

EptinezumaB in Real-world evidence: Multicenter, Real Life, Cohort Study in Migraine.

NCT05570149

Status	RECRUITING
Sponsor	IRCCS San Raffaele Roma
Enrollment	500 participants

Key Eligibility Criteria

Inclusion (5)

- Age between 18 and 75 years;
- Males and females;
- Willingness to sign the informed consent;
- High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
- Chronic migraine, according to the ICHD-III criteria;

Exclusion (4)

- Other headaches different than migraine;
- Known intolerance to eptinezumab or excipients;
- Current treatment with other mAbs;
- Vascular disease or Raynaud.

Locations (1 total)

IRCCS San Raffaele Roma, Roma, RM, Italy